The leading causes of vision impairment and blindness are posterior segment-related diseases including age-related macular degeneration,diabetic macular edema and endophthalmitis.Recently,pharmaceutical approaches to ...The leading causes of vision impairment and blindness are posterior segment-related diseases including age-related macular degeneration,diabetic macular edema and endophthalmitis.Recently,pharmaceutical approaches to these diseases have used steroids and oligonucleotides.These drugs are usually administered via invasive injection because noninvasive delivery method such as eye drop administration of drugs is not available.However,repeated injections are associated with potential risks of complications.Moreover,patients may not comply with such regimens.展开更多
Introduction:Presbyopia affects people from the 4^(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life.A non-invasive pharmaco...Introduction:Presbyopia affects people from the 4^(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life.A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia.The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia.Results:Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses.Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly.It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it.Conclusion:Despite the lack of a completely well understood mechanism,pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients.The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series.Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia.展开更多
文摘The leading causes of vision impairment and blindness are posterior segment-related diseases including age-related macular degeneration,diabetic macular edema and endophthalmitis.Recently,pharmaceutical approaches to these diseases have used steroids and oligonucleotides.These drugs are usually administered via invasive injection because noninvasive delivery method such as eye drop administration of drugs is not available.However,repeated injections are associated with potential risks of complications.Moreover,patients may not comply with such regimens.
文摘Introduction:Presbyopia affects people from the 4^(th) decade of life and is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life.A non-invasive pharmacological treatment providing near-lenses independence would be a truly groundbreaking approach in the treatment of presbyopia.The purpose of this review is to analyze the emerging pharmacological solutions proposed to address presbyopia.Results:Several ophthalmic eye drops compounds solutions have been described in peer-reviewed papers or presented in ophthalmological tabloids and congresses.Each topical treatment deals with drug combinations aimed to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocularly or binocularly.It remains unclear how much each drug in the final combined form is involved in the achievement of the outcome and contributes to it.Conclusion:Despite the lack of a completely well understood mechanism,pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopic patients.The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series.Complete studies are needed to confirm which will be the more effective pharmacological compound for the treatment of presbyopia.
